Immix Biopharma (NASDAQ:IMMX - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $7.00 target price on the stock. HC Wainwright's price target indicates a potential upside of 250.88% from the stock's current price.
Immix Biopharma Stock Performance
NASDAQ IMMX traded up $0.01 during trading hours on Monday, reaching $2.00. 51,842 shares of the company's stock were exchanged, compared to its average volume of 83,819. The company has a market capitalization of $54.88 million, a price-to-earnings ratio of -2.35 and a beta of 0.24. The company's 50-day moving average is $2.13 and its two-hundred day moving average is $1.93. Immix Biopharma has a one year low of $1.26 and a one year high of $3.80.
Immix Biopharma (NASDAQ:IMMX - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.08). Research analysts predict that Immix Biopharma will post -0.87 earnings per share for the current fiscal year.
Institutional Trading of Immix Biopharma
A number of institutional investors have recently modified their holdings of the company. SBI Securities Co. Ltd. bought a new position in shares of Immix Biopharma during the fourth quarter worth about $38,000. FNY Investment Advisers LLC acquired a new position in Immix Biopharma during the 4th quarter worth approximately $63,000. Finally, Geode Capital Management LLC grew its stake in shares of Immix Biopharma by 5.6% during the 3rd quarter. Geode Capital Management LLC now owns 150,082 shares of the company's stock worth $224,000 after acquiring an additional 7,954 shares in the last quarter. 11.26% of the stock is currently owned by institutional investors.
Immix Biopharma Company Profile
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Articles
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
